Advanced Diagnostic and Treatment Methods in Alzheimer's Disease
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".
Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 10747
Special Issue Editor
Interests: computational biomedicine; biomarkers; neuroscience; infectious diseases; cancer
Special Issue Information
Dear Colleagues,
Alzheimer's disease (AD) is a form of dementia and the most common progressive neurodegenerative disease. Alzheimer's disease affects approximately 50 million individuals worldwide according to estimates. It is predicted that this number will rise to 150 million by 2050 unless new preventative medicines or very effective diagnostic tools are developed.
In AD, oxidative stress resulting from mitochondrial dysfunction is posited to result from pathological progress yet to be determined. Additionally, targeting amyloid-beta (Aβ) aggregation is one of the most widely used strategies to manage AD, and efforts are being made globally to develop peptide-based compounds for an efficient early diagnosis and treatment. Peptides are a special pharmacological agent that falls between small molecules and proteins. This vast pool of bioactive compounds holds considerable potential for treating hitherto difficult-to-treat oncological, metabolic, viral, and neurological diseases. The latest studies have led to the development of drugs that target Aβ (β and γ-Secretase inhibitors) to reduce the amount of Aβ formed, even though these inhibitors might be associated with harmful side effects, low efficacy, and inability to cross the blood–brain barrier. Furthermore, phytocompounds, especially alkaloids, were known for their anti-AD treatment value applications, based on in vitro and in vivo studies, along with anti-aggregating compounds, metal chelators, and anti-oxidative agents, and anti-inflammatory drugs.
To provide a dynamic insight into the AD challenge, this Special Issue aims to reveal anti-AD treatments and additional computational tools for early diagnosis and prediction of the disease and other comorbidities.
We invite authors to submit original research and review articles that focus on, but are not limited to, the following potential topics:
- Alzheimer's disease;
- Amyloid-beta;
- Antidiabetic drugs in neurodegeneration;
- Cancer and Alzheimer’s disease;
- Computational biomedicine;
- Cubosomes;
- Drug targets;
- In silico;
- Lipids;
- Machine learning approach;
- Mitochondria;
- Neurodegeneration;
- Neuroinflammation;
- Oxidative stress;
- Phytocompounds in Alzheimer’s disease;
- Β secretase and γ-secretase inhibitors.
Dr. Athanasios Alexiou
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer's disease
- amyloid-beta
- antidiabetic drugs in neurodegeneration
- cancer and Alzheimer's disease
- computational biomedicine
- cubosomes
- drug targets
- insilico
- lipids
- machine-learning approach
- mitochondria
- neurodegeneration
- neuroinflammation
- oxidative stress
- phytocompounds in Alzheimer's disease
- β secretase and γ-secretase inhibitors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.